» Articles » PMID: 19504041

Behavioral and Quantitative Mitochondrial Proteome Analyses of the Effects of Simvastatin: Implications for Models of Neural Degeneration

Overview
Specialties Neurology
Physiology
Date 2009 Jun 9
PMID 19504041
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, simvastatin, is used for lowering elevated low-density lipoprotein cholesterol concentrations. This translates into reduced cardiovascular disease-related morbidity and mortality, while the drugs' anti-oxidant and anti-inflammatory properties have earmarked it as a potential treatment strategy against various neurological conditions. Statins have been shown to protect neurons from degeneration in a number of animal models. Although no mechanism completely explains the multiple benefits exerted by statins, emerging evidence suggests that in some degenerative and brain injury models, mitochondrial impairment may play a contributive rate. However, [corrected] evidence lacks to support a directly influencing role for statins on mitochondria-related proteins and motor behavior. Mitochondrial dysfunction may increase oxygen free radical production, which in turn leaves cells susceptible to energy failure, apoptosis and related events [corrected] which could prove fatal. The potential link between simvastatin treatment and mitochondrial function would be supported if key mitochondrial proteins were altered by simvastatin exposure. Using mass spectroscopy (MS), we identified 24 mitochondrial proteins that differed significantly (P < 0.05) in relative abundancy as a result of simvastatin treatment. The identified proteins represented many facets of mitochondrial integrity, with the majority forming part of the electron transport chain machinery, which is necessary for energy production. In a follow-up study, we then addressed whether simvastatin is capable of altering sensorimotor function in a mitochondrial toxin-induced animal model. Rats were pre-treated with simvastatin for 14 days, followed by a single unihemispheric (substantia nigra; SN) injection of rotenone, a mitochondrial complex I (Co-I) inhibitor. Results showed that simvastatin improved motor performance in rotenone-infused rats. The data are consistent with the possibility that alteration of mitochondrial function may contribute to the beneficial effects associated with statin use.

Citing Articles

Isolated Mitochondrial Preparations and Assays: A Powerful and Relevant Tool for Assessment of Brain (Patho)physiology.

Ahmad F, Ramamorthy S, Areeshi M, Ashraf G, Haque S Curr Neuropharmacol. 2023; 21(6):1433-1449.

PMID: 36872352 PMC: 10324330. DOI: 10.2174/1570159X21666230303123555.


A Combined N-terminomics and Shotgun Proteomics Approach to Investigate the Responses of Human Cells to Rapamycin and Zinc at the Mitochondrial Level.

Bons J, Macron C, Aude-Garcia C, Vaca-Jacome S, Rompais M, Cianferani S Mol Cell Proteomics. 2019; 18(6):1085-1095.

PMID: 31154437 PMC: 6553941. DOI: 10.1074/mcp.RA118.001269.


Identification of simvastatin-regulated targets associated with JNK activation in DU145 human prostate cancer cell death signaling.

Jung E, Chung K, Kim C BMB Rep. 2017; 50(9):466-471.

PMID: 28803608 PMC: 5625694. DOI: 10.5483/bmbrep.2017.50.9.087.


Comparative mitochondrial proteomics: perspective in human diseases.

Jiang Y, Wang X J Hematol Oncol. 2012; 5:11.

PMID: 22424240 PMC: 3337254. DOI: 10.1186/1756-8722-5-11.


Striatal neuroprotection with methylene blue.

Rojas J, Simola N, Kermath B, Kane J, Schallert T, Gonzalez-Lima F Neuroscience. 2009; 163(3):877-89.

PMID: 19596056 PMC: 2765788. DOI: 10.1016/j.neuroscience.2009.07.012.

References
1.
Hirokawa N . Cross-linker system between neurofilaments, microtubules, and membranous organelles in frog axons revealed by the quick-freeze, deep-etching method. J Cell Biol. 1982; 94(1):129-42. PMC: 2112203. DOI: 10.1083/jcb.94.1.129. View

2.
Dauer W, Przedborski S . Parkinson's disease: mechanisms and models. Neuron. 2003; 39(6):889-909. DOI: 10.1016/s0896-6273(03)00568-3. View

3.
Vega G, Weiner M, Lipton A, von Bergmann K, Lutjohann D, Moore C . Reduction in levels of 24S-hydroxycholesterol by statin treatment in patients with Alzheimer disease. Arch Neurol. 2003; 60(4):510-5. DOI: 10.1001/archneur.60.4.510. View

4.
Weitzdoerfer R, Fountoulakis M, Lubec G . Aberrant expression of dihydropyrimidinase related proteins-2,-3 and -4 in fetal Down syndrome brain. J Neural Transm Suppl. 2002; (61):95-107. DOI: 10.1007/978-3-7091-6262-0_8. View

5.
Goldman J, Yen S, Chiu F, Peress N . Lewy bodies of Parkinson's disease contain neurofilament antigens. Science. 1983; 221(4615):1082-4. DOI: 10.1126/science.6308771. View